GT BIOPHARMA, INC.: 10-Q filed 2011-11-21
What GT BIOPHARMA, INC. reported in its quarterly report filed 2011-11-21 (fiscal Q3 2011): 25 published measures, 72 facts as tagged in accession 0001513160-11-000069.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2011-11-21
- Fiscal period
- fiscal Q3 2011
- Accession
- 0001513160-11-000069 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All GT BIOPHARMA, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 371,000 | USD | |
| At 2010-12-31 | 185,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | -4,906,000 | USD | |
| At 2010-12-31 | -5,469,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 0 | USD | |
| At 2010-12-31 | 54,000 | USD | |
| At 2010-09-30 | 181,000 | USD | |
| At 2009-12-31 | 1,293,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 23,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | -2,562,000 | USD | 273 |
| 2010-07-01 to 2010-09-30 | -633,000 | USD | 92 |
| 2010-01-01 to 2010-09-30 | -2,333,000 | USD | 273 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-09-30 | -639,000 | USD | 273 |
| 2010-01-01 to 2010-09-30 | -1,158,000 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-09-30 | 585,000 | USD | 273 |
| 2010-01-01 to 2010-09-30 | 46,000 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | -82,657,000 | USD | |
| At 2010-12-31 | -80,095,000 | USD |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 0 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 0 | USD | 273 |
| 2010-07-01 to 2010-09-30 | 0 | USD | 92 |
| 2010-01-01 to 2010-09-30 | 0 | USD | 273 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-09-30 | 126,000 | USD | 273 |
| 2010-01-01 to 2010-09-30 | 569,000 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | -541,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | -2,880,000 | USD | 273 |
| 2010-07-01 to 2010-09-30 | -654,000 | USD | 92 |
| 2010-01-01 to 2010-09-30 | -1,970,000 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 343,000 | USD | |
| At 2010-12-31 | 137,000 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | -117,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | -465,000 | USD | 273 |
| 2010-07-01 to 2010-09-30 | -23,000 | USD | 92 |
| 2010-01-01 to 2010-09-30 | -422,000 | USD | 273 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 5,277,000 | USD | |
| At 2010-12-31 | 5,654,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 974,000 | USD | |
| At 2010-12-31 | 625,000 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 28,000 | USD | |
| At 2010-12-31 | 48,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 535,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 2,855,000 | USD | 273 |
| 2010-07-01 to 2010-09-30 | 654,000 | USD | 92 |
| 2010-01-01 to 2010-09-30 | 1,970,000 | USD | 273 |
Gross profit
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | -6,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | -25,000 | USD | 273 |
| 2010-07-01 to 2010-09-30 | 0 | USD | 92 |
| 2010-01-01 to 2010-09-30 | 0 | USD | 273 |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 535,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 2,806,000 | USD | 273 |
| 2010-07-01 to 2010-09-30 | 588,000 | USD | 92 |
| 2010-01-01 to 2010-09-30 | 1,810,000 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 0 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 49,000 | USD | 273 |
| 2010-07-01 to 2010-09-30 | 66,000 | USD | 92 |
| 2010-01-01 to 2010-09-30 | 160,000 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 238,622,616 | shares | |
| At 2010-12-31 | 149,571,976 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 77,509,000 | USD | |
| At 2010-12-31 | 74,474,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 557,000 | USD | |
| At 2010-12-31 | 414,000 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 23,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | -2,562,000 | USD | 273 |
| 2010-07-01 to 2010-09-30 | -633,000 | USD | 92 |
| 2010-01-01 to 2010-09-30 | -2,333,000 | USD | 273 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-09-30 | 20,000 | USD | 273 |
| 2010-01-01 to 2010-09-30 | 21,000 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 564,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 318,000 | USD | 273 |
| 2010-07-01 to 2010-09-30 | 21,000 | USD | 92 |
| 2010-01-01 to 2010-09-30 | -363,000 | USD | 273 |
Inspect the source
- Entity
- GT BIOPHARMA, INC. / CIK 0000109657
- Captured
- 2026-09-19T14:55:07.505Z
- SEC response SHA-256
0714d67deac3d58f2a709d6724403717be9f1cb5b62a0b01bb00eb4ad237a7b1
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000109657.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))